RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorPonce, S.
dc.contributor.authorBrendel, K.
dc.contributor.authorSpigel, D. R.
dc.contributor.authorChen, Y.
dc.contributor.authorJove Casulleras, M.
dc.contributor.authorJuan-Vidal, O.
dc.contributor.authorRich, P.
dc.contributor.authorHayes, T.
dc.contributor.authorGutierrez Calderon, V.
dc.contributor.authorBernabe Caro, R.
dc.contributor.authorNavarro, A.
dc.contributor.authorDowlati, A.
dc.contributor.authorZhang, B.
dc.contributor.authorMoore, Y.
dc.contributor.authorKokhreidze, J.
dc.contributor.authorPedret-Dunn, A.
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorBunn, P. A.
dc.contributor.authoraffiliation[Ponce, S.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Paz-Ares, L.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Brendel, K.] Ipsen, Dept Oncol, Paris, France
dc.contributor.authoraffiliation[Spigel, D. R.] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
dc.contributor.authoraffiliation[Chen, Y.] Med Oncol Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA
dc.contributor.authoraffiliation[Jove Casulleras, M.] Hosp Duran & Reynals, Inst Catala Oncol, Inst Catala Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Juan-Vidal, O.] Hosp Univ & Politecn La Fe, Valencia, Spain
dc.contributor.authoraffiliation[Rich, P.] Canc Treatment Ctr Amer, Atlanta, GA USA
dc.contributor.authoraffiliation[Hayes, T.] South West Healthcare, Warrnambool, Australia
dc.contributor.authoraffiliation[Gutierrez Calderon, V.] Hosp Reg Univ Malaga, Malaga, Spain
dc.contributor.authoraffiliation[Bernabe Caro, R.] Hosp Univ Virgen del Rocio, Seville, Spain
dc.contributor.authoraffiliation[Navarro, A.] Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Navarro, A.] Univ Hosp, Barcelona, Spain
dc.contributor.authoraffiliation[Dowlati, A.] Case Western Reserve Univ, Cleveland, OH 44106 USA
dc.contributor.authoraffiliation[Zhang, B.] Ipsen, Cambridge, MA USA
dc.contributor.authoraffiliation[Moore, Y.] Ipsen, Cambridge, MA USA
dc.contributor.authoraffiliation[Kokhreidze, J.] Ipsen, Cambridge, MA USA
dc.contributor.authoraffiliation[Pedret-Dunn, A.] Ipsen, Oxford, England
dc.contributor.authoraffiliation[Bunn, P. A.] Univ Colorado, Med Oncol, Denver, CO 80202 USA
dc.contributor.funderIpsen
dc.date.accessioned2025-01-07T12:24:09Z
dc.date.available2025-01-07T12:24:09Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.1554
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420415509/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24579
dc.identifier.wosID573469102377
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS1038-S1039
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleRESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía